Loading... (0%)
About liver disease

GENFIT: A COMPREHENSIVE APPROACH TO NASH

NIS4: Our blood-based diagnostic test for the identification of patients with NASH...
LEARN MORE
Health prevention, medical education, dissemination of information related to NASH...
ACCESS WEBSITE

COMPANY LIFE

We are a late-stage biopharmaceutical company dedicated to high unmet medical needs.
Learn more
Find out our about current job opportunities or submit your spontaneous application explaining your project.
LEARN MORE

DOCUMENTATION

Press releases
  • FDA and EMA Grant GENFIT’s Elafibranor Orphan Drug Designation for Primary Biliary Cholangitis (PBC)
    07/29/2019
  • GENFIT: Half-Year report of Liquidity Contract with Crédit Industriel et Commercial
    07/09/2019
  • GENFIT and Terns Pharmaceuticals Announce $228MM Strategic Partnership to Develop and Commercialize Elafibranor in Greater China
    06/24/2019
  • GENFIT: Outcome of the Ordinary Shareholder’s Meeting of June 13, 2019
    06/13/2019
  • GENFIT Announces Active Participation in the 2nd Annual International NASH Day
    06/12/2019
Events
Praesent tempus ipsum accumsan leo ut quis, Praesent consectetur Curabitur libero.